192 related articles for article (PubMed ID: 25942537)
1. Epigenetic modifiers in normal and malignant hematopoiesis.
Haladyna JN; Yamauchi T; Neff T; Bernt KM
Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
[TBL] [Abstract][Full Text] [Related]
2. Alterations to
Venugopal K; Feng Y; Shabashvili D; Guryanova OA
Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
[TBL] [Abstract][Full Text] [Related]
3. Reduced levels of two modifiers of epigenetic gene silencing, Dnmt3a and Trim28, cause increased phenotypic noise.
Whitelaw NC; Chong S; Morgan DK; Nestor C; Bruxner TJ; Ashe A; Lambley E; Meehan R; Whitelaw E
Genome Biol; 2010; 11(11):R111. PubMed ID: 21092094
[TBL] [Abstract][Full Text] [Related]
4. The DNA methylation landscape of hematological malignancies: an update.
Blecua P; Martinez-Verbo L; Esteller M
Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
[TBL] [Abstract][Full Text] [Related]
5. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
6. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
7. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
Rao RC; Dou Y
Nat Rev Cancer; 2015 Jun; 15(6):334-46. PubMed ID: 25998713
[TBL] [Abstract][Full Text] [Related]
8. Cytosine modifications in myeloid malignancies.
Meldi KM; Figueroa ME
Pharmacol Ther; 2015 Aug; 152():42-53. PubMed ID: 25956466
[TBL] [Abstract][Full Text] [Related]
9. Metabolic consequences of oncogenic IDH mutations.
Parker SJ; Metallo CM
Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.
Lee SC; Miller S; Hyland C; Kauppi M; Lebois M; Di Rago L; Metcalf D; Kinkel SA; Josefsson EC; Blewitt ME; Majewski IJ; Alexander WS
Blood; 2015 Jul; 126(2):167-75. PubMed ID: 26036803
[TBL] [Abstract][Full Text] [Related]
11. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Raj U; Kumar H; Gupta S; Varadwaj PK
Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
[TBL] [Abstract][Full Text] [Related]
12. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
13. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.
Kim E; Ilagan JO; Liang Y; Daubner GM; Lee SC; Ramakrishnan A; Li Y; Chung YR; Micol JB; Murphy ME; Cho H; Kim MK; Zebari AS; Aumann S; Park CY; Buonamici S; Smith PG; Deeg HJ; Lobry C; Aifantis I; Modis Y; Allain FH; Halene S; Bradley RK; Abdel-Wahab O
Cancer Cell; 2015 May; 27(5):617-30. PubMed ID: 25965569
[TBL] [Abstract][Full Text] [Related]
14. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
Campbell JE; Kuntz KW; Knutson SK; Warholic NM; Keilhack H; Wigle TJ; Raimondi A; Klaus CR; Rioux N; Yokoi A; Kawano S; Minoshima Y; Choi HW; Porter Scott M; Waters NJ; Smith JJ; Chesworth R; Moyer MP; Copeland RA
ACS Med Chem Lett; 2015 May; 6(5):491-5. PubMed ID: 26005520
[TBL] [Abstract][Full Text] [Related]
15. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
16. Enigmas of IDH mutations in hematology/oncology.
Heuser M; Araujo Cruz MM; Goparaju R; Chaturvedi A
Exp Hematol; 2015 Aug; 43(8):685-97. PubMed ID: 26032956
[TBL] [Abstract][Full Text] [Related]
17. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.
Goyama S; Kitamura T
Cancer Sci; 2017 Apr; 108(4):553-562. PubMed ID: 28100030
[TBL] [Abstract][Full Text] [Related]
19. Genetics factors associated with myelodysplastic syndromes.
Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
[TBL] [Abstract][Full Text] [Related]
20. [Roles of mTORC1 in acute myeloid leukemia].
Hoshii T; Hirao A
Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
